钠-葡萄糖协同转运蛋白2抑制剂的肾脏保护作用
本文综述SGLT2抑制剂肾脏保护作用的机制与临床证据。EMPA-REG OUTCOME显示恩格列净降低主要心血管不良事件、死亡率、心衰住院及糖尿病肾病进展;CANVAS显示卡格列净降低3点MACE、心衰风险和肾脏复合终点,但增加下肢截肢和骨折风险。指南推荐高危患者考虑SGLT2抑制剂以降低心血管风险。
要点
- EMPA-REG OUTCOME显示恩格列净降低MACE、死亡率、心衰住院及糖尿病肾病进展。
- CANVAS显示卡格列净降低MACE、心衰风险和肾脏复合终点,但增加截肢和骨折风险。
- 指南推荐高危患者考虑SGLT2抑制剂以降低心血管风险。
核心结论
- SGLT2抑制剂在心血管高危的2型糖尿病患者中具有肾脏保护作用,可降低肾脏复合终点风险。
研究设计与样本
- 本文为综述,总结EMPA-REG OUTCOME和CANVAS等试验证据及指南推荐。
主要发现
- EMPA-REG OUTCOME中恩格列净降低主要心血管不良事件、死亡率、心衰住院和糖尿病肾病进展。
- CANVAS中卡格列净降低3点MACE、心衰风险和肾脏复合终点,但增加下肢截肢和骨折风险。
关键数值与推荐
- 指南推荐在高危患者亚组中考虑SGLT2抑制剂以降低心血管风险。
- 正在进行的以肾脏为主要终点的试验将指导CKD患者(伴或不伴糖尿病)的治疗。
临床怎么用
- 对心血管高危的2型糖尿病患者,可考虑使用SGLT2抑制剂以降低心血管和肾脏事件风险。
- 使用卡格列净时需注意下肢截肢和骨折风险。
局限性
- 本文为综述,未报告原始研究数据;SGLT2抑制剂在CKD患者中的肾脏保护作用尚待正在进行的试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past two years, our understanding of anti-hyperglycemic medications used to treat patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG OUTCOME trial, agents used to lower blood glucose were felt to prevent or delay the development of microvascular complications, but were not known to definitively reduce cardiovascular risk or mortality. Previous studies with then novel sodium-glucose cotransport-2 (SGLT2) inhibitors demonstrated improvements in several cardiovascular and renal risk factors, including HbA1c, blood pressure, weight, renal hyperfiltration, and albuminuria. However, as with other antihyperglycemic drugs, it could not be known if these salutary effects would translate into improved cardiorenal outcomes. In the EMPA-REG OUTCOME trial, SGLT2 inhibition with empagliflozin reduced the primary outcome of major adverse cardiovascular events (MACE), while also reducing mortality, hospitalization for heart failure, and progression of diabetic kidney disease. In the CANVAS Program trials using canagliflozin, the rates of the 3-point MACE endpoint, the risk of heart failure and the renal composite endpoint were also reduced, albeit with an increased risk of lower extremity amputation and fracture. As a result, clinical practice guidelines recommend the consideration of SGLT2 inhibition in high-risk patient subgroups for cardiovascular risk reduction. Ongoing primary renal endpoint trials will inform the cardio-metabolic-renal community about how to optimally treat patients with chronic kidney disease - including those with and without diabetes. Our aim is to review the rationale for renal protection with SGLT2 inhibitors, and their current place in the clinical management of patients with kidney disease.
引用
- Heerspink HJL, Kosiborod M, Inzucchi SE, et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018. PMID: 29735306. doi:10.1016/j.kint.2017.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。